Status
Conditions
Treatments
About
The purpose of this study is to evaluate the safety and efficacy of Human Urinary Kallidinogenase combined with endovascular therapy in acute ischemic stroke (AIS) patients with large vessel occlusion.
Full description
A prospective, randomized, double-blind, placebo-controlled, multi-center study of Human Urinary Kallidinogenase or Placebo, combined with endovascular therapy for AIS patients with large vessel occlusion.
Approximately 120 eligible subjects will be randomized (1:1) to receive one of the following treatments for 10 days:
The safety of Human Urinary Kallidinogenase will be evaluated through 90±7 days.
End of study evaluation will occur at day 90±7 or premature discontinuation.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
120 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Wenjie Cao, M.D.; Qiang Dong, M.D.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal